Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Obesity and brain structure in schizophrenia – ENIGMA study in 3021 individuals

  • McWhinney, Sean R.
  • Crespo-Facorro, Benedicto
  • Tordesillas-Gutiérrez, Diana
  • Hajek, Tomas
Hajek, Tomas: et al., Schizophrenia is frequently associated with obesity, which is linked with neurostructural alterations. Yet, we do not understand how the brain correlates of obesity map onto the brain changes in schizophrenia. We obtained MRI-derived brain cortical and subcortical measures and body mass index (BMI) from 1260 individuals with schizophrenia and 1761 controls from 12 independent research sites within the ENIGMA-Schizophrenia Working Group. We jointly modeled the statistical effects of schizophrenia and BMI using mixed effects. BMI was additively associated with structure of many of the same brain regions as schizophrenia, but the cortical and subcortical alterations in schizophrenia were more widespread and pronounced. Both BMI and schizophrenia were primarily associated with changes in cortical thickness, with fewer correlates in surface area. While, BMI was negatively associated with cortical thickness, the significant associations between BMI and surface area or subcortical volumes were positive. Lastly, the brain correlates of obesity were replicated among large studies and closely resembled neurostructural changes in major depressive disorders. We confirmed widespread associations between BMI and brain structure in individuals with schizophrenia. People with both obesity and schizophrenia showed more pronounced brain alterations than people with only one of these conditions. Obesity appears to be a relevant factor which could account for heterogeneity of brain imaging findings and for differences in brain imaging outcomes among people with schizophrenia., NAC et al. were supported by the Agencia Nacional de Investigación y Desarrollo, Chile, through its grants PIA ACT1414, ANID-PIA-ACT 192064, and FONDECYT regular 1200601. This work was funded by the German Research Foundation (DFG, grant FOR2107 DA1151/5-1 and DA1151/5-2 to UD; SFB-TRR58, Projects C09 and Z02 to UD) and the Interdisciplinary Center for Clinical Research (IZKF) of the medical faculty of Münster (grant Dan3/012/17 to UD). The NUDZ and IKEM sites were supported by funding from the Ministry of Health of the Czech Republic (16-32791A, NU20-04-00393) and conceptual development of research organization (Institute for Clinical and Experimental Medicine – IKEM, IN 00023001). This work was also funded by the German Research Foundation (DFG grant FOR2107, KI588/14-1 and FOR2107, KI588/14-2 to TTJK, Marburg, Germany), as well as, the Alexander von Humboldt Foundation, EU and Deutsche Forschungsgemeinschaft (DFG), grants NE2254/1-2, NE2254/3-1, NE2254/4-1. Additional support provided by research grants from the National Healthcare Group, Singapore (SIG/05004; SIG/05028), and the Singapore Bioimaging Consortium (RP C009/2006) research grants awarded to KS. EW was supported by the European Union’s Horizon 2020 research and innovation programme (Early Cause, grant n° 848158). Funding for TWW was provided by the National Health and Medical Research Council Australia Project Grant 568807; New South Wales Health, University of New South Wales, Neuroscience Research Australia and the Schizophrenia Research Institute. GD’s research was funded by the European Research Council 677467 and Science Foundation Ireland 16/ERCS/3787. VDC was supported by NIH R01MH118695. PMT was supported by NIMH grant R01MH116147. Lastly, TH was supported by funding from the Canadian Institutes of Health Research (103703, 106469 and 142255), Nova Scotia Health Research Foundation, Dalhousie Clinical Research Scholarship to TH, Brain & Behavior Research Foundation (formerly NARSAD); 2007 Young Investigator and 2015 Independent Investigator Awards to TH., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Brain ageing in schizophrenia: evidence from 26 international cohorts via the ENIGMA Schizophrenia consortium

  • Constantinides, Constantinos
  • Crespo-Facorro, Benedicto
  • Tordesillas-Gutiérrez, Diana
  • Walton, Esther
C. Constantinides et al., Schizophrenia (SZ) is associated with an increased risk of life-long cognitive impairments, age-related chronic disease, and premature mortality. We investigated evidence for advanced brain ageing in adult SZ patients, and whether this was associated with clinical characteristics in a prospective meta-analytic study conducted by the ENIGMA Schizophrenia Working Group. The study included data from 26 cohorts worldwide, with a total of 2803 SZ patients (mean age 34.2 years; range 18-72 years; 67% male) and 2598 healthy controls (mean age 33.8 years, range 18-73 years, 55% male). Brain-predicted age was individually estimated using a model trained on independent data based on 68 measures of cortical thickness and surface area, 7 subcortical volumes, lateral ventricular volumes and total intracranial volume, all derived from T1-weighted brain magnetic resonance imaging (MRI) scans. Deviations from a healthy brain ageing trajectory were assessed by the difference between brain-predicted age and chronological age (brain-predicted age difference [brain-PAD]). On average, SZ patients showed a higher brain-PAD of +3.55 years (95% CI: 2.91, 4.19; I2 = 57.53%) compared to controls, after adjusting for age, sex and site (Cohen's d = 0.48). Among SZ patients, brain-PAD was not associated with specific clinical characteristics (age of onset, duration of illness, symptom severity, or antipsychotic use and dose). This large-scale collaborative study suggests advanced structural brain ageing in SZ. Longitudinal studies of SZ and a range of mental and somatic health outcomes will help to further evaluate the clinical implications of increased brain-PAD and its ability to be influenced by interventions., The ENIGMA Schizophrenia Working Group acknowledges the National Institutes of Health (NIH) Big Data to Knowledge (BD2K) award for foundational support and consortium development (Grant No. U54 EB020403 to PMT). CC was supported by grant MR/N0137941/1 for the GW4 BIOMED Doctoral Training Partnership awarded to the Universities of Bath, Bristol, Cardiff and Exeter from the Medical Research Council (MRC)/ UK Research & Innovation (UKRI). JHC was supported by a UKRI Innovation Fellowship (MR/R024790/2). LE was supported by Desert-Pacific Mental Illness Research Education and Clinical Center, US, NIH grant R01MH083968-05. TH was funded by the German Research Foundation (DFG grants HA7070/2-2, HA7070/3, HA7070/4 to TH). LH was supported by a Rubicon fellowship (grant number 452020227) provided by The Dutch Research Council (NWO). NJ and LS were supported by NIH grant R01 MH117601. NJ was also supported by NIH grants R01AG059874, R01MH11760. LS was also supported by a National Health and Medical Research Council (NHMRC) Career Development Fellowship (1140764) and a University of Melbourne Dame Kate Campbell fellowship. PMT was supported in part by NIH grant R01 MH116147. EW was supported by the European Union Horizon 2020 research and innovation programme (EarlyCause, grant number 848158). Acknowledgements for the various participating data contributors follow - ASRB: the Australian Schizophrenia Research Bank (ASRB) was supported by NHMRC (Enabling Grant, ID 386500), the Pratt Foundation, Ramsay Health Care, the Viertel Charitable Foundation and the Schizophrenia Research Institute. CP was also supported by a NHMRC Senior Principal Research Fellowship (1105825), an NHMRC L3 Investigator Grant (1196508). CSW was funded by the NSW Ministry of Health, Office of Health and Medical Research and a recipient of a National Health and Medical Research Council (Australia) Principal Research Fellowship (PRF) (#1117079). CAMH: the datasets were generated and shared with support from the CAMH Foundation and the Canadian Institutes of Health Research. CASSI: this study was supported by NHMRC grant 568807 (awarded to CSW and TW). CSW was funded by the NSW Ministry of Health, Office of Health and Medical Research and a recipient of a NHMRC (Australia) Principal Research Fellowship (PRF) (#1117079). COBRE: the study and investigators were supported by NIH grants R01MH118695, R01MH121101, as well as National Science Foundation (NSF) grant 2112455 (awarded to VC). JT (senior author) was supported by NIH grant R01MH121246. EONCKS: all processing of contributed neuroimaging data was conducted on the Centre for High Performance Computing, Cape Town, South Africa. ESO: the study and investigators (AC, FS, DT) was funded by the Ministry of Health, Czech Republic - Conceptual Development of Research Organization (Institute for Clinical and Experimental Medicine – IKEM, IN 00023001), and Ministry of Health of the Czech Republic, grants nr. NU20-04-00393 and NU21-08-00432. FBIRN: The study was supported by National Institutes of Health grant numbers: NIH 1 U24 RR021992 (Function Biomedical Informatics Research Network), NIH 1 U24 RR025736 (Biomedical Informatics Research Network Coordinating). FBIRN data was processed by the UCI High Performance Computing cluster supported by Joseph Farran, Harry Mangalam, and Adam Brenner and the NCRR and the National Center for Advancing Translational Sciences. JT (senior author) was also supported by NIH grant R01MH121246. FIDMAG: this study was supported by Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and the Catalonian Government, Generalitat de Catalunya (2017-SGR-1271 to EP-C from AGAUR). PFC was supported by a Sara Borrell contract (CD19/00149), funded by Instituto de Salud Carlos III, co-funded by the European Union (European Regional Development Fund/European Social Fund [ERDF/ESF], “Investing in your future”). FSLRome: the IRCCS Santa Lucia Foundation of Rome study (FSLRome) was partially supported by the Italian Ministry of Health (RC12-13-14-15A Grant) and by the European Commission ERA-Net NEURON joint transnational calI 2010 (European Research Projects on Mental Disorders: NEUCONNECT). GROUP: This work was supported by the Geestkracht program of the Dutch Health Research Council (ZON-MW, grant number: 10-000-1002), and the European Community’s Seventh Framework Program under grant agreement No. HEALTH-F2-2009-241909 (Project EU-GEI). Huilong: this study was funded by the National Natural Science Foundation of China (81761128021;31671145;81401115;81401133), Beijing Municipal Science & Technology Commission grant (Z141107002514016) and Beijing Natural Science Foundation (7162087, Beijing Municipal Administration of Hospitals Clinical medicine Development of special funding (XMLX201609; zylx201409). IGP: The Imaging Genetics in Psychosis (IGP) study was supported by NHMRC Project Grant APP630471, APP1051673, APP1081603 (awarded to MJG), and the Macquarie University’s ARC Centre of Excellence in Cognition and its Disorders (CE110001021). MJG was supported by an Australian Research Council Future Fellowship (FT0991511; 2009-13) and a R.D. Wright Biomedical Career Development Award from the NHMRC (1061875; 2014-17). IMH: this study was supported by the National Healthcare Group, Singapore (SIG/05004; SIG/05028) and the Singapore Bioimaging Consortium (RP C009/06) research grants (awarded to KS). iRELATE: this study was supported by grants to GD from the European Research Council (ERC-2015-STG-677467) and Science Foundation Ireland (SFI-16/ERCS/3787). JBNU: YC was supported by the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant no. HI18C2383). Madrid: this research was supported by the Spanish Ministry of Science and Innovation; Instituto de Salud Carlos III (grants SAM16PE07CP1, PI16/02012, and PI19/01024 awarded to CAra; PI17/01249 awarded JJ; and PI17/00481, JR19/00024 and PI20/00721 awarded to CMD-C), co-financed by ERDF Funds from the European Commission, “A way of making Europe”, CIBERSAM; Madrid Regional Government (B2017/BMD-3740 AGES-CM-2 awarded to CAra), European Union Structural Funds; European Union Seventh Framework Program under grant agreements FP7-4-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7- HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7- HEALTH-2013-2.2.1-2-602478 (Project METSY) awarded to Cara; and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS awarded to CAra), Fundación Familia Alonso and Fundación Alicia Koplowitz. MCIC: this work was primarily supported by the Department of Energy (DE-FG02- 99ER62764) and the Mind Research Network. VC was also supported by NSF (grant no. 2112455) and NIH (grant no. R01MH118695, R01MH121101). MPRC: support was received from NIH grants R01MH123163, R01EB015611, R01NS114628 (awarded to PK). PAFIP: this study has been funded by Instituto de Salud Carlos III through the project PI17/01056 (co-funded by ERDF/ESF “A way to make Europe”/“Investing in your future”). RSCZ: the study was supported by National Institutes of Health grant number: NIMH R21MH097196 to TGMvE. SCORE: this study was supported in part by grant 3232BO_119382 from the Swiss National Science Foundation., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Beyond the global brain differences: Intraindividual variability differences in 1q21.1 distal and 15q11.2 BP1-BP2 deletion carriers

  • Boen, Rune
  • Crespo-Facorro, Benedicto
  • Tordesillas-Gutiérrez, Diana
Rune Boen, et al., [Background]: Carriers of the 1q21.1 distal and 15q11.2 BP1-BP2 copy number variants exhibit regional and global brain differences compared with noncarriers. However, interpreting regional differences is challenging if a global difference drives the regional brain differences. Intraindividual variability measures can be used to test for regional differences beyond global differences in brain structure., [Methods]: Magnetic resonance imaging data were used to obtain regional brain values for 1q21.1 distal deletion (n = 30) and duplication (n = 27) and 15q11.2 BP1-BP2 deletion (n = 170) and duplication (n = 243) carriers and matched noncarriers (n = 2350). Regional intra-deviation scores, i.e., the standardized difference between an individual's regional difference and global difference, were used to test for regional differences that diverge from the global difference., [Results]: For the 1q21.1 distal deletion carriers, cortical surface area for regions in the medial visual cortex, posterior cingulate, and temporal pole differed less and regions in the prefrontal and superior temporal cortex differed more than the global difference in cortical surface area. For the 15q11.2 BP1-BP2 deletion carriers, cortical thickness in regions in the medial visual cortex, auditory cortex, and temporal pole differed less and the prefrontal and somatosensory cortex differed more than the global difference in cortical thickness., [Conclusions]: We find evidence for regional effects beyond differences in global brain measures in 1q21.1 distal and 15q11.2 BP1-BP2 copy number variants. The results provide new insight into brain profiling of the 1q21.1 distal and 15q11.2 BP1-BP2 copy number variants, with the potential to increase understanding of the mechanisms involved in altered neurodevelopment., 1000BRAINS. This work was supported by the Institute of Neuroscience and Medicine (INM-1), Research Centre Julich, European Union’s Horizon 2020 Research and Innovation Programme (Grant No. 945539 [HBP SGA3; SC]), and Joint Lab Supercomputing and Modeling for the Human Brain. We thank the Heinz Nixdorf Foundation for the generous support of the Heinz Nixdorf Study. We also thank the scientists and the study staff of the Heinz Nixdorf Recall Study and 1000BRAINS. We gratefully acknowledge the computing time granted through JARA-HPC on the supercomputer JURECA at Forschungszentrum Julich. TOP: This work was supported by Research Council of Norway (Grant Nos. 23273 (Centre of Excellence, Norwegian Centre for Mental Disorders, NORMENT), Grant Nos. 324252 and 226971). ENIGMA-CNV Working Group. This work was supported by the Research Council of Norway (Grant No. 223273 [to OAA]), South-Eastern Norway Regional Health Authority (Grant No. 2020060 [to IES, RB]), European Union’s Horizon 2020 Research and Innovation Programme (CoMorMent project; Grant No. 847776 [to IES]), Kristian Gerhard Jebsen Stiftelsen (Grant No. SKGJ-MED-021 [to IES]), and National Institute of Mental Health (NIMH) (Grant Nos. U01MH119736, R21MH116473, R01MH085953 [to CEB]), and 1R01MH129858-01A1 [to SJ]. This work was performed on Services for Sensitive Data, University of Oslo, with resources provided by UNINETT Sigma2, the national infrastructure for high performance computing and data storage in Norway. Australian Schizophrenia Research Bank: This work was supported by the Australian National Health and Medical Research Council (NHMRC) (Enabling Grant No. 386500, L3 Investigator Grant No. 1196508 [to CP]), and Program Grant No. APP1150083 [to CP]), Pratt Foundation, Ramsay Health Care, Viertel Charitable Foundation, and Schizophrenia Research Institute. Chief Investigators for the Australian Schizophrenia Research Bank were Vaughan Carr, US, RJS, Assen Jablensky, BJM, Patricia Michie, Stanley Catts, FAH, and CP. ECHO-DEFINE: This work was supported by the Wellcome Trust (Institutional Strategic Support Fund [to MBMvdB] and Clinical Research Training Fellowship Grant No. 102003/Z/13/Z [to JLD]), Waterloo Foundation (Grant No. WF 918-1234 [to MBMvdB]), Baily Thomas Charitable Fund (Grant No. 2315/1 [to MBMvdB]), NIMH (Grant Nos. 5UO1MH101724 and U01MH119738 [to MBMvdB]), IMAGINE-ID and IMAGINE-2 studies (funded by Medical Research Council Grant Nos. MR/N022572/1 and MR/T033045/1 [to MBMvdB]), and Medical Research Council (Centre Grant No. MR/P005748/1 [to MJO]). The DEFINE study was supported by a Wellcome Trust Strategic Award (Grant No. 100202/Z/12/Z [to MJO]). FOR2107 Marburg and Münster: This work is part of the German multicenter consortium “Neurobiology of Affective Disorders: A Translational Perspective on Brain Structure and Function,” supported by the German Research Foundation (Deutsche Forschungsgemeinschaft; Forschungsgruppe/Research Unit FOR2107). Principal investigators with respective areas of responsibility in the FOR2107 consortium: Work Package WP1, FOR2107/MACS cohort and brainimaging: TK (speaker FOR2107; DFG Grant Nos. KI 588/14-1, KI 588/14-2, KI 588/20-1, and KI 588/22-1), UD (co-speaker FOR2107; Grant Nos. DA 1151/5-1, DA 1151/5-2, and DA 1151/6-1), Axel Krug (Grant Nos. KR 3822/5-1 and KR 3822/7-2), IN (Grant Nos. NE 2254/1-2, NE 2254/3-1, and NE 2254/4-1), Carsten Konrad (Grant No. KO 4291/3-1). WP5, genetics: Marcella Rietschel (Grant Nos. RI 908/11-1 and RI 908/11-2), MMN (Grant Nos. NO 246/10-1 and NO 246/10-2), Stephanie Witt (Grant Nos. WI 3439/3-1 and WI 3439/3-2). WP6, multi-method data analytics: AJ (Grant Nos. JA 1890/7-1 and JA 1890/7-2), TH (Grant No. HA 7070/2-2). We are deeply indebted to all study participants and staff. A list of acknowledgments can be found at: www.for2107.de/acknowledgements. UCLA-Utrecht: This work was supported by the NIMH (Grant No. R01 MH090553 [to RAO]). The NIMH had no further role in study design, in the collection, analysis, and interpretation of the data, in the writing of the report, and in the decision to submit the paper for publication. QTIM: This work was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (Grant No. R01 HD050735) and the NHMRC (Grant Nos. 486682 and 1009064). Genotyping was supported by the NHMRC (Grant No. 389875). BETULA: This work was supported by the Knut and Alice Wallenberg Foundation (scholar grant [to LN]). Freesurfer calculations were enabled by resources provided by the Swedish National Infrastructure for Computing at HPC2N, Umeå. SHIP (Study of Health in Pomerania): This work is part of the Community Medicine Research net of the University of Greifswald, Germany, which is supported by the Federal Ministry of Education and Research (Grant Nos. 01ZZ9603, 01ZZ0103, and 01ZZ0403), Ministry of Cultural Affairs, and Social Ministry of the Federal State of Mecklenburg-West Pomerania. Genome-wide data in SHIP have been supported by the Federal Ministry of Education and Research (Grant No. 03ZIK012) and a joint grant from Siemens Healthineers and the Federal State of Mecklenburg-West Pomerania. MRI scans in SHIP and SHIP-TREND have been supported by a joint grant from Siemens Healthineers and the Federal State of Mecklenburg-West Pomerania. PAFIP (Programa de Atención a las Fases Iniciales de Psicosis): This work was supported by the Instituto de Salud Carlos III (Grant Nos. 00/3095, 01/3129, PI020499, PI14/00639, PI17/01056, and PI14/00918), SENY Fundació (Research Grant No. CI2005 0308007), and Fundación Marqués de Valdecilla Instituto de Investigación Sanitaria Valdecilla (Grant Nos. A/02/07, NCT0235832, and NCT02534363). Osaka: This work was supported by the Japan Agency for Medical Research and Development (Grant Nos. JP21wm0425012, JP18dm0307002, JP22wm0525019, and JP22dk0207060) and Japan Society for the Promotion of Science KAKENHI (Grant Nos. JP20H03611, JP22H04926, and 20K15778). Some computations were performed at the Research Center for Computational Science, Okazaki, Japan (Project: NIPS, 18-IMS-C162, 19-IMS-C181, 20-IMS-C162, 21-IMS-C179, 22-IMS-C195). IMAGEN: This work was supported by the European Union–funded FP6 Integrated Project IMAGEN (Reinforcement-Related Behavior in Normal Brain Function and Psychopathology) (Grant No. LSHM-CT-2007-037286), Horizon 2020–funded ERC Advanced Grant STRATIFY (Brain Network Based Stratification of Reinforcement-Related Disorders) (Grant No. 695313), Medical Research Foundation and Medical Research Council (Grants Nos. MR/R00465X/1 and MRF-058-0004-RG-DESRI [Neurobiological Underpinning of Eating Disorders: Integrative Biopsychosocial Longitudinal Analyses in Adolescents] and MR/S020306/1 and MRF-058-0009-RG-DESR-C0759 [Establishing Causal Relationships Between Biopsychosocial Predictors and Correlates of Eating Disorders and Their Mediation by Neural Pathways]), National Institutes of Health (NIH) (Consortium Grant No. U54 EB020403, supported by a cross-NIH alliance that funds Big Data to Knowledge Centres of Excellence, and Grant No. 1R56AG058854-01), National Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London, ERANID (Understanding the Interplay Between Cultural, Biological and Subjective Factors in Drug Use Pathways) (Grant No. PR-ST-0416-10004), BRIDGET (JPND: BRain Imaging, cognition Dementia and next generation GEnomics) (Grant No. MR/N027558/1), Human Brain Project (HBP SGA 2) (Grant No. 785907), FP7 project MATRICS (Grant No. 603016), Medical Research Council Grant Consortium on Vulnerability to Externalizing Disorders and Addictions (Grant No. MR/N000390/1), Bundesministerium für Bildung und Forschung (Grant Nos. 01GS08152, 01EV0711, Forschungsnetz AERIAL 01EE1406A, and 01EE1406B), Deutsche Forschungsgemeinschaft (Grant Nos. SM 80/7-2, SFB 940/2, and NE 1383/14-1), Agence Nationale de la Recherche (ANR) (Grant Nos. ANR-12-SAMA-0004 and AAPG2019 [GeBra]), Eranet Neuron (Grant Nos. AF12-NEUR0008-01 [WM2NA], ANR-18-NEUR00002-01 [ADORe], and ANR-12-SAMA-0004), Fondation de France (Grant No. 00081242), Fondation pour la Recherche Médicale (Grant No. DPA20140629802), Mission Interministérielle de Lutte contre les Drogues et les Conduites Addictives, Assistance Publique Hôpitaux de Paris and Institut National de la Santé et de la Recherche Médicale (Interface Grant), Paris Sud University IDEX 2012, Fondation de l’Avenir (Grant No. AP-RM-17-013), and Fédération pour la Recherche sur le Cerveau. MCIC (Mind Clinical Imaging Consortium): This work was supported by the NIH (NIH/National Center for Research Resources Grant No. P41RR14075 [to VC] and Grant No. R01EB005846 [to VC]), Department of Energy (Grant No. DE-FG02-99ER62764), Mind Research Network, Morphometry Biomedical Informatics Research Network (Grant Nos. 1U24 and RR021382A), Function Biomedical Informatics Research Network (Grant No. U24RR021992-01 [to VC], NIH/National Center for Research Resources Grant No. MO1 RR025758-01 [to VC], and NIMH Grant No. 1RC1MH089257 [to VC]), Deutsche Forschungsgemeinschaft (research fellowship [to SE]), and Brain and Behavior Research Foundation (NARSAD Young Investigator Award [to SE]). NTR (Netherlands Twin Register): This work was supported by the Netherlands Organization for Scientific Research (NWO) and Netherlands Organisation for Health Research and Development (Grant Nos. 904-61-090, 985-10-002, 912-10-020, 904-61-193, 480-04-004,463-06-001, 451-04-034, 400-05-717, Addiction-31160008, 016-115-035, 481-08-011, 056-32-010, Middelgroot-911-09-032, OCW_NWO Gravity programme—024.001.003, and NWO-Groot 480-15-001/674), Center for Medical Systems Biology (NWO Genomics), NBIC/BioAssist/RK (Grant No. 2008.024), Biobanking and Biomolecular Resources Research Infrastructure The Netherlands (Grant Nos. 184.021.007 and 184.033.111), Spinozapremie (Grant No. NWO-56-464-14192), Royal Netherlands Academy of Arts and Sciences Academy Professor Award (Grant No. PAH/6635) and University Research Fellow grant (to DIB), Amsterdam Public Health research institute (former EMGO+ Institute for Health and Care Research), Amsterdam Neuroscience (former Neuoscience Campus Amsterdam), European Science Foundation (Grant No. EU/QLRT-2001-01254), European Community’s Seventh Framework Programme (FP7- HEALTH-F4-2007-2013, Grant Nos. 01413: ENGAGE and 602768: ACTION), European Research Council (Grant Nos. ERC Starting 284167, ERC Consolidator 771057, and ERC Advanced 230374), Rutgers University Cell and DNA Repository (NIMH Grant No. U24 MH068457-06), NIH (Grant Nos. R01D0042157-01A1, R01MH58799-03, MH081802, DA018673, and R01 DK092127-04 and Grand Opportunity Grant Nos. 1RC2 MH089951 and 1RC2 MH089995), and Avera Institute for Human Genetics. The genotyping and analyses were partly funded by the Genetic Association Information Network of the Foundation for the National Institutes of Health. Computing was supported by NWO (Grant No. 2018/EW/00408559), BiG Grid, Dutch e-Science Grid, and SURFsara. OATS (Older Australian Twins Study): This work was supported by the NHMRC and Australian Research Council Strategic Award Grant of the Ageing Well, Ageing Productively Program (Grant No. 401162), NHMRC project (seed) grants (Grant Nos. 1024224 and 1025243), NHMRC project grants (Grant Nos. 1045325 and 1085606), and NHMRC program grants (Grant Nos. 568969 and 1093083). The OATS Study was facilitated through access to Twins Research Australia, a national resource supported by a Centre of Research Excellence Grant (Grant No. 1079102) from the NHMRC. We thank the participants for their time and generosity in contributing to this research. We acknowledge the contribution of the OATS research team (https://cheba.unsw.edu.au/project/older-australian-twins-study) to this study. PING (Pediatric Imaging, Neurocognition, and Genetics): This work was supported by the National Institute on Drug Abuse and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (Grant Nos. RC2DA029475 and R01 HD061414). EPIGEN-London/University College London: The work was partly undertaken at University College London Hospitals NHS Foundation Trust/University College London, which received a proportion of funding from the UK Department of Health National Institute for Health Research Biomedical Research Centres funding scheme. We thank the Wolfson Trust and the Epilepsy Society for supporting the Epilepsy Society MRI scanner. OSR (Istituto di Ricovero e Cura a Carattere Scientifico Ospedale San Raffele)-Milan: This work was supported by the European Union H2020 (EU.3.1.1 Grant No. 754740 MOODSTRATIFICATION.EU), Italian Ministry of Health (Grant No. RF-2018-12367249) and Italian Ministry of University and Scientific Research (Grant No. A_201779W93T). Dublin: This work was supported by the European Research Council (Grant No. ERC-2015-STG-677467 [to GD]) and Science Foundation Ireland (Grant No. SFI-16/ERCS/3787 [to GD]). Brain Imaging Genetics (BIG): This work makes use of the BIG database, first established in Nijmegen, the Netherlands, in 2007. This resource is now part of Cognomics (www.cognomics.nl), a joint initiative by researchers from the Donders Centre for Cognitive Neuroimaging, Human Genetics and Cognitive Neuroscience departments of Radboud University Medical Centre, and Max Planck Institute for Psycholinguistics in Nijmegen. The Cognomics Initiative is supported by the participating departments and centers and Biobanking and Biomolecular Resources Research Infrastructure (Netherlands), Hersenstichting Nederland, and NWO. The research leading to these results also receives funding from the NWO (Gravitation Grant No. 024.001.006 Language in Interaction), European Community’s Seventh Framework Programme (FP7/2007-2013) (Grant Nos. 602450 IMAGEMEND, 278948 TACTICS, and 602805 Aggressotype), European Community’s Horizon 2020 programme (Grant Nos. 643051 MiND, and ERC-2010-AdG 268800-NEUROSCHEMA). In addition, the work was supported by the ENIGMA Consortium (Grant No. U54 EB020403) from the BD2K Initiative of a cross-NIH partnership. UK Biobank: This research has been conducted using the UK Biobank Resource under Application Number 27412. OAA has received speaker’s honorarium from Lundbeck, Janssen, and Sunovion and is a consultant to Coretechs.ai. TRM reports personal fees from Pfizer, Lundbeck, Astellas, Janssen, and Angelini outside the submitted work. He is an employee and shareholder of Pasithea Therapeutics. CRKC has received partial research support from Biogen for work unrelated to the topic of this article (principal investigator, PMT). PMT has received partial research support from Biogen for work unrelated to the topic of this article. MBMvdB and MJO report grants from Takeda Pharmaceuticals outside the submitted work. MJO reports a grant from Akrivia Health outside the submitted work. HJG has received travel grants and speaker’s honoraria from Fresenius Medical Care, Neuraxpharm, Servier, and Janssen as well as research funding from Fresenius Medical Care. GS has received honoraria for participating at advisory board meetings from Roche and Biogen regarding new Alzheimer’s disease drugs. KKS has received consultant and speaker’s honoraria from Roche and OrionPharma, reimbursement of travel and accommodation costs at a meeting from Kolpharma, and sponsorships for arranging conferences from Desitin and Eisai AB. IG has received speaker’s honorarium from Lundbeck. MMN has received fees for membership in an advisory board from HMG Systems Engineering GmbH, for membership in the Medical-Scientific Editorial Office of the Deutsches Ärzteblatt, and for serving as a consultant for Everis Belgium in a project of the European Commission (REFORM/SC2020/029). MMN also receives salary payments from Life & Brain GmbH and holds shares in Life & Brain GmbH. All these concerned activities outside the submitted work. CP received honoraria for talks from Lundbeck, Australia Pty Ltd. outside the submitted work. DJS has received consultancy honoraria from Discovery Vitality, Johnson & Johnson, Kanna, L’Oreal, Lundbeck, Orion, Sanofi, Servier, Takeda and Vistagen. JH has received speaker’s honorarium from Medice and Takeda outside the submitted work. KP reports work with Novo Nordisk and Roche clinical trials outside the submitted work. All other authors report no biomedical financial interests or potential conflicts of interest., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Penetrance of neurodevelopmental copy number variants is associated with variations in cortical morphology

  • Silva, Ana I.
  • Crespo-Facorro, Benedicto
  • Tordesillas-Gutiérrez, Diana
  • Linden, David E. J.
  • ENIGMA-CNV Working Group
ENIGMA-CNV Working Group: et al, [Background] Copy number variants (CNVs) may increase the risk for neurodevelopmental conditions. The neurobiological mechanisms that link these high-risk genetic variants to clinical phenotypes are largely unknown. An important question is whether brain abnormalities in individuals who carry CNVs are associated with their degree of penetrance., [Methods] We investigated whether increased CNV penetrance for schizophrenia and other developmental disorders was associated with variations in cortical and subcortical morphology. We pooled T1-weighted brain magnetic resonance imaging and genetic data from 22 cohorts from the ENIGMA (Enhancing Neuro Imaging Genetics through Meta Analysis)-CNV consortium. In the main analyses, we included 9268 individuals (aged 7–90 years, 54% female), from which we identified 398 carriers of 36 neurodevelopmental CNVs at 20 distinct loci. A secondary analysis was performed including additional neuroimaging data from the ENIGMA-22q consortium, including 274 carriers of the 22q11.2 deletion and 291 noncarriers. CNV penetrance was estimated through penetrance scores that were previously generated from large cohorts of patients and controls. These scores represent the probability risk of developing either schizophrenia or other developmental disorders (including developmental delay, autism spectrum disorder, and congenital malformations)., [Results] For both schizophrenia and developmental disorders, increased penetrance scores were associated with lower surface area in the cerebral cortex and lower intracranial volume. For both conditions, associations between CNV-penetrance scores and cortical surface area were strongest in regions of the occipital lobes, specifically in the cuneus and lingual gyrus., [Conclusions] Our findings link global and regional cortical morphometric features with CNV penetrance, providing new insights into neurobiological mechanisms of genetic risk for schizophrenia and other developmental disorders., 16p11.2 Consortium: This work was supported by Compute Canada, the Brain Canada Multi investigator research initiative, Canada First Research Excellence Fund, the Institute of Data Valorization, and Healthy Brain Healthy Lives. SJ is a recipient of a Canada Research Chair in neurodevelopmental disorders and a chair from the Jeanne et Jean Louis Levesque Foundation. This work was supported by the Canadian Institutes of Health Research (CIHR) (Grant Nos. 400528 and 438531) and Innovative Medicines Initiative 2 Joint Undertaking (Grant No. 777394) for AIMS-2-TRIALS. This Joint Undertaking receives support from the EU’s Horizon 2020 program, EFPIA, Autism Speaks, Autistica, and SFARI. KK was supported by The Institute of Data Valorization Postdoctoral Fellowship program, through the Canada First Research Excellence Fund. COBRE (Centers of Biomedical Research Excellence): This research is funded by National Science Foundation (Grant No. 2112455) and National Institutes of Health (NIH) (Grant No. R01MH118695). Dublin: This research is funded by European Research Council (Grant No. 677467). ECHO-DEFINE: The ECHO (Experiences of Children with Copy Number Variants) study acknowledges funding from the Wellcome Trust (Institutional Strategic Support Fund) (to MBMvdB) and Clinical Research Training Fellowship (Grant No. 102003/Z/13/Z [to JLD]), the Waterloo Foundation (Grant No. WF 918- 1234 [to MBMvdB]), the Baily Thomas Charitable Fund (Grant No. 2315/1 [to MBMvdB]), National Institute of Mental Health (NIMH) (Grant No. 5UO1MH101724) and NIMH (Grant No. U01MH119738 [to MBMvdB]), the IMAGINE-ID and IMAGINE-2 studies (funded by Medical Research Council [MRC]) (Grant Nos. MR/N022572/1 and MR/T033045/1 [to MBMvdB]) and an MRC Centre Grant (Grant No. MR/P005748/1 [to MJO]). The DEFINE (Defining Endophenotypes From Integrative Neuroscience) study was supported by a Wellcome Trust Strategic Award (Grant No. 100202/Z/12/Z [to MJO]). ENIGMA: The ENIGMA Working Group acknowledges the NIH Big Data to Knowledge award for foundational support and consortium development (Grant No. U54 EB020403 [to PMT]). For a complete list of ENIGMA-related grant support, please see here: http://enigma.ini.usc.edu/about-2/funding/. PMT and SIT are also supported in part by ENIGMA NIH (Grant Nos. R01MH116147, R01NS107513, R01AG058854, and R01MH129742). IES is supported by the Research Council of Norway (Grant No. 223273), South-Eastern Norway Regional Health Authority (Grant No. 2020060), European Union’s Horizon2020 Research and Innovation Programme (CoMorMent project) (Grant No. 847776), and Kristian Gerhard Jebsen Stiftelsen (Grant No. SKGJ-MED-021). South-Eastern Norway Regional Health Authority (Grant No. 2020060) also supports RBo. This work was partially performed on Services for Sensitive Data (TSD), University of Oslo, Norway, with resources provided by UNINETT Sigma2, the National Infrastructure for High Performance Computing and Data Storage in Norway. OAA is supported by Research Council of Norway (Grant No. 223273) and KG Jebsen Stiftelsen (Grant No. SKGJ-MED-021). NJ is supported by NIH (Grant No. R01MH117601). DvdM is supported by Research Council of Norway (Grant No. 276082). ENIGMA-22q: This research is supported by NIMH (Grant Nos. R01MH085953, R21MH116473, and 9U01MH119736-02). ASB is supported by the Dalglish Family Chair in 22q11.2 Deletion Syndrome, CIHR (Grant Nos. MOP-79518, MOP-89066, MOP-97800, and MOP-111238) and NIMH (Grant No. U01MH101723–01[3/5]). EWCC acknowledges support from the CIHR (Grant No. MOP-74631) and Ontario Mental Health Foundation for the current work. DRR is supported by NIMH (Grant No. R01 119185). JES is supported by the Stanford Maternal and Child Health Research Institute Uytengsu-Hamilton 22q11 Neuropsychiatry Research Awards Program (Grant No. UH22QEXTFY21). DMM-M acknowledges support from NIMH (Grant No. U01MH119737). JASV acknowledges funding support from NIMH (Grant Nos. 1U01MH119741-01 and 3U01MH119741-02S1). TvA acknowledges financial support from NIMH (Grant No. 5U01 MH119740). GAP: PD’s research is supported by the MRC and the Wellcome Trust. Funding was received from the Psychiatry Research Trust, the Wellcome Trust, the MRC, and the National Institute for Health Research (NIHR) Biomedical Research Centre at the South London and Maudsley NHS Trust. The funding sources were not involved in carrying out or interpreting the study. GOBS: The GOBS (Genetics of Brain Structure and Function study) data collection was supported in part by NIH (Grant Nos. R01MH078143 and R01MH083824). Haavik: This research is supported by Stiftelsen KG Jebsen (Grant No. SKGJ MED-02), the Research Council of Norway, and Helse Vest RHF. HUBIN (Human Brain Informatics): This research is supported by Swedish Research Council (Grant Nos. K2007-62X-15077-04-1, K2008-62P-20597-01-3, K2010-62X-15078-07-2, K2012-61X-15078-09-3, K2015-62X-15077-12-3, and 2017-00949), the regional agreement on medical training and clinical research between Stockholm County Council and the Karolinska Institutet, and the Research Council of Norway (Grant No. 274 359). HUNT: The HUNT (Trøndelag Health Study) is a collaboration between HUNT Research Centre (Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology), North Trøndelag County Council, Central Norway Health Authority, and the Norwegian Institute of Public Health. HUNT-MRI was funded by the Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology and the Norwegian National Advisory Unit for functional MRI. IMAGEN: The European Union–funded FP6 Integrated Project IMAGEN (Reinforcement-related behavior in normal brain function and psychopathology) (Grant No. LSHM-CT- 2007-037286), the Horizon 2020 funded ERC Advanced Grant STRATIFY (Brain network based stratification of reinforcement-related disorders) (Grant No. 695313), Human Brain Project (Grant Nos. HBP SGA 2, 785907, and HBP SGA 3, 945539), the MRC Grant c-VEDA (Consortium on Vulnerability to Externalizing Disorders and Addictions) (Grant No. MR/N000390/1), NIH (Grant No. R01DA049238), A decentralized macro and micro gene-by-environment interaction analysis of substance use behavior and its brain biomarkers), the NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London, the Bundesministerium für Bildung und Forschung (Grant Nos. 01GS08152; 01EV0711; Forschungsnetz AERIAL 01EE1406A, 01EE1406B; Forschungsnetz IMAC- Mind 01GL1745B), the Deutsche Forschungsgemeinschaft (DFG Grant Nos. SM 80/7-2, SFB 940, TRR 265, NE 1383/14-1), ImagenPathways “Understanding the Interplay between Cultural, Biological and Subjective Factors in Drug Use Pathways” is a collaborative project supported by the European Research Area Network on Illicit Drugs, the Medical Research Foundation and MRC (Grant Nos. MR/R00465X/1 and MR/S020306/1), the NIH-funded ENIGMA (Grant Nos. 5U54EB020403-05 and 1R56AG058854-01), National Natural Science Foundation of China (NSFC) (Grant No. 82 150 710 554), and European Union–funded project environMENTAL (Grant No. 101057429). Additional support was provided by grants from the ANR (Grant Nos. ANR-12-SAMA-0004, AAPG2019—GeBra), the Eranet Neuron (Grant Nos. AF12-NEUR0008-01—WM2NA; and ANR-18-NEUR00002-01—ADORe), the Fondation de France (Grant No. 00081242), the Fondation pour la Recherche Médicale (Grant No. DPA20140629802), the Mission Interministérielle de Lutte-contre-les-Drogues-et-les-Conduites-Addictives, the Assistance Publique-Hôpitaux de Paris and Institut National de la Santé et de la Recherche Médicale (INSERM) (interface grant), Paris Sud University IDEX 2012, the Fondation de l’Avenir (Grant No. AP-RM-17-013), the Fédération pour la Recherche sur le Cerveau; the NIH, Science Foundation Ireland (Grant No. 16/ERCD/3797), the Science Foundation Ireland (Grant No. 16/ERCD/3797), the NIH (Axon, Testosterone and Mental Health during Adolescence) (Grant No. R01MH085772-01A1), and the NIH Consortium (Grant No. U54 EB020403), supported by a cross-NIH alliance that funds Big Data to Knowledge Centres of Excellence. The INSERM, the Strasbourg University, and SATT CONECTUS, provided sponsorship (principal investigator: J-LM). TP is supported by NIH (Grant No. R01MH085772). Gilles Berstchy is acknowledged for his support. Stephane Lehericy and the radiographer staff at Centre de NeuroImagerie de Recherche de l'’Institut du Cerveau (http://www.cenir.org/mri.html?lang=en) are acknowledged for their support in acquisition of MRI datasets. MCIC (Mind Clinical Imaging Consortium): This research is funded by NIH study P20GM103472. METH-CT: DJS is supported by the South African Medical Research Council (SAMRC). FS is supported by a PDRF (Presidential Doctoral Research Fellowship) from the Brain Behavior Unit, Department of Psychiatry and Mental Health, University of Cape Town. SD is supported by the Biomedical Research and Innovation Platform and SAMRC. NCNG: NCNG (Norwegian Cognitive NeuroGenetics sample) was supported by the Bergen Research Foundation, the University of Bergen, the Research Council of Norway (FUGE) (Enhance Research in Functional Genomics) (Grant Nos. 151904 and 183327), Psykisk Helse (Grant No. 175345), RCN (Grant Nos. 154313/V50 [to Ivar Reinvang] and 177458/V50 [to TE]), Helse SørØst RHF (Grant No. 2012086 [to TE]), and the Dr. Einar Martens Fund. NTR: The NTR cohort was supported by the Netherlands Organization for Scientific Research (NWO) and The Netherlands Organization for Health Research and Development (ZonMW) (Grant Nos. 904-61-090, 985-10-002, 912-10-020, 904-61-193, 480-04-004, 463-06-001, 451-04-034, 400-05-717, Addiction-31160008, 016-115-035, 481-08-011, 400-07-080, 056-32-010, Middelgroot-911-09-032, OCW_NWO Gravity program –024.001.003, NWO-Groot 480-15-001/674), Center for Medical Systems Biology (CMSB, NWO Genomics), NBIC/BioAssist/RK(2008.024), Biobanking and Biomolecular Resources Research Infrastructure (BBMRI) (Grant Nos. NL, 184.021.007 and 184.033.111), X-Omics 184-034-019; Spinozapremie (Grant No. NWO- 56-464-14192), KNAW Academy Professor Award (PAH/6635) and University Research Fellow grant (to DIB); Amsterdam Public Health Research Institute (former EMGO+), Neuroscience Amsterdam research institute (former NCA); the European Community’s Fifth and Seventh Framework Program (Grant Nos. FP5- LIFE QUALITY-CT-2002-2006, FP7-HEALTH-F4-2007-2013, Grant No. 01254: GenomEUtwin, Grant No. 01413: ENGAGE and Grant No. 602768:ACTION); the European Research Council (Grant Nos. ERC Starting 284 167, ERC Consolidator 771057, ERC Advanced 230374), Rutgers University Cell and DNA Repository (NIMH) (Grant No. U24 MH068457-06), NIH (Grant Nos. R01D0042157-01A1, R01MH58799-03, MH081802, DA018673, R01DK092127-04), Grand Opportunity (Grant Nos. 1RC2 MH089951 and 1RC2 MH089995); and the Avera Institute for Human Genetics, Sioux Falls, South Dakota. Part of the genotyping and analyses were funded by the Genetic Association Information Network of the Foundation for the NIH. Computing was supported by NWO (Grant No. 2018/EW/00408559), BiG Grid, the Dutch e-Science Grid, and SURFSARA. OATS1/OATS2 and Sydney MAS: The OATS (Older Australian Twins Study) has been funded by a National Health & Medical Research Council (NHMRC) and Australian Research Council (ARC) Strategic Award Grant of the Ageing Well, Ageing Productively Program (Grant No. 401162); NHMRC Project (seed) Grants (Grant Nos. 1024224 and 1 025 243); NHMRC Project Grants (Grant Nos. 1045325 and 1085606); and NHMRC Program Grants (Grant Nos. 568969 and 1093083). This research was facilitated through access to Twins Research Australia, which is a national resource supported by a Centre of Research Excellence Grant (Grant No. 1079102) from the NHMRC. The Sydney Memory and Ageing Study has been funded by 3 NHMRC Program Grants (Grant Nos. ID350833, ID568969, and APP1093083). Core funding was received from the NSW Government Department of Health and the Australian government Department of Health and Aged Care; NHMRC Leadership Fellowship (Grant No. GNT2009771); NHMRC (Grant No. GNT1045325). DNA samples were extracted by Genetic Repositories Australia, an Enabling Facility, which was supported by an NHMRC Grant (Grant No. 401184). MRI scans were processed with the support of NHMRC Project Grants (Grant Nos. 510175 and 1025243) and an ARC Discovery Project Grant (Grant No. DP0774213) and John Holden Family Foundation. PAFIP: This study was supported by grants from Carlos III Health Institute (Grant Nos. IPI17/00402, PI17/01056, PI14/00639, and PI14/00918) cofunded by the European Union through FEDER funds and Fundación Instituto de Investigación Marqués de Valdecilla (Grant Nos. NCT0235832 and NCT02534363). No pharmaceutical company has financially supported the study. JV-B acknowledges IDIVAL Grants (Grant Nos. INT/A21/10 and INT/A20/04). QTIM: The QTIM study was supported by grants from the U.S. National Institute of Child Health and Human Development (Grant No. R01HD050735) and the Australian NHMRC (Grant Nos. 486682, 1009064). Genotyping was supported by NHMRC (Grant No. 389875). AFM is funded by an ARC Future Fellowship (Grant No. FT200100837). SEM is supported by NHMRC Investigator Grant (Grant No. APP1172917). SHIP-2/SHIP-TREND: SHIP is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (Grant Nos. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs as well as the Social Ministry of the Federal State of Mecklenburg-West Pomerania, and the network “Greifswald Approach to Individualized Medicine (GANI_MED)” funded by the Federal Ministry of Education and Research (Grant No. 03IS2061A). Genome-wide data have been supported by the Federal Ministry of Education and Research (Grant No. 03ZIK012) and a joint grant from Siemens Healthineers and the Federal State of Mecklenburg-West Pomerania. The University of Greifswald is a member of the Caché Campus program of the InterSystems GmbH. This study has received funding from the following institutions: Federal Ministry of Education and Research, the Ministry of Cultural Affairs, as well as the Social Ministry of the Federal State of Mecklenburg-West Pomerania. MRI examinations were supported by Siemens Healthineers, Siemens Healthcare GmbH. AT has been funded by DFG (Grant No. 542489987). The SHIP authors thank Holger Prokisch and Thomas Meitinger (Helmholtz Zentrum München) for the genotyping of the SHIP-TREND cohort. Stroke (TOP_T3): The European Research Council under the European Union’s Horizon 2020 research and Innovation program (Grant No. ERC 802998). The Research Council of Norway (Grant Nos. 298646 and 300767), and the South-Eastern Norway Regional Health Authority (Grant Nos. 2013054, 2015044, 2015073, 2018076, 2019101, and 2020060)., Peer reviewed